atorvastatin
not tagged
['cardio']
stop-ca results: incidence of the primary endpoint at 12 months was 9% in the atorvastatin group and 22% in the placebo group (p=0.002) incidence of secondary endpoint was 13% in the atorvastatin group and 29% in the placebo group (p=0.001) #acc23 #wccardio 
Official account representing the ACC's #JACCJournals, one of the most widely read & most impactful CV journal programs in the world. @ACCinTouch #JACC